A detailed history of Manufacturers Life Insurance Company, The transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 10,817 shares of ITOS stock, worth $78,531. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,817
Previous 11,071 2.29%
Holding current value
$78,531
Previous $164,000 32.93%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$10.09 - $17.97 $2,562 - $4,564
-254 Reduced 2.29%
10,817 $110,000
Q2 2024

Aug 14, 2024

BUY
$10.33 - $18.09 $7,127 - $12,482
690 Added 6.65%
11,071 $164,000
Q1 2024

May 14, 2024

BUY
$9.89 - $13.64 $840 - $1,159
85 Added 0.83%
10,381 $141,000
Q2 2023

Aug 11, 2023

BUY
$12.93 - $18.05 $22,511 - $31,425
1,741 Added 20.35%
10,296 $136,000
Q2 2022

Aug 15, 2022

SELL
$16.57 - $35.1 $141,756 - $300,280
-8,555 Closed
0 $0
Q1 2022

Aug 11, 2023

BUY
$31.92 - $47.45 $273,075 - $405,934
8,555 New
8,555 $275,000
Q1 2022

May 20, 2022

SELL
$31.92 - $47.45 $69,266 - $102,966
-2,170 Reduced 20.23%
8,555 $275,000
Q4 2021

Feb 16, 2022

SELL
$26.23 - $47.86 $3,567 - $6,508
-136 Reduced 1.25%
10,725 $499,000
Q3 2021

Nov 12, 2021

SELL
$23.91 - $29.58 $21,519 - $26,622
-900 Reduced 7.65%
10,861 $293,000
Q2 2021

Aug 12, 2021

BUY
$17.9 - $36.1 $15,232 - $30,721
851 Added 7.8%
11,761 $302,000
Q1 2021

May 03, 2021

BUY
$30.86 - $44.2 $129,673 - $185,728
4,202 Added 62.64%
10,910 $373,000
Q4 2020

Feb 12, 2021

BUY
$21.59 - $33.95 $144,825 - $227,736
6,708 New
6,708 $227,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $258M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.